There are two FDA approved drugs acting through regulation of SMO mediated signalling pathway: vismodegib (GDC-0449) (ref. 17) and sonidegib (LDE-225) (ref. 25) for the treatment of basal cell carcinoma. The gene discussed is SMO; the disease is basal cell carcinoma.